

Head of Bertarelli Foundation Gene Therapy Platform Campus Biotech Genève, CH

Education & Training

DOCTOR OF PHILOSOPHY

1995 - 2001 Gene Therapy University of Lausanne - CH

POSTDOCTORAL FELLOW


2001-2003 EPFL, Lausanne, Switzerland

ASSISTANT SCIENTIST

2003-2006 University of Wisconsin USA

SENIOR SCIENTIST

2007 - Present EPFL, Lausanne, Switzerland



Profile

Bernard Schneider is a prominent and a neuroscientist Research Teaching Associate at the Brain Mind Institute of EPFL. He leads the Bertarelli Gene Therapy Platform, focusing on developing viral vectors for therapies targeting neurodegenerative diseases and sensory organ disorders, such as ALS, deafness, and blindness. With over 16 years of experience in neuroscience, Dr. Schneider has authored more than 100 publications and is a key figure in translational research

Articles

- Long term peripheral AAV9-SMN gene therapy promotes survival in a mouse model of spinal muscular atrophy
- Stable isotope labeling and ultra-highresolution NanoSIMS imaging reveal alpha-synuclein-induced changes in neuronal metabolism in vivo
- Recovery of walking after paralysis by regenerating characterized neurons to their natural target region



linkedin.com/in/bernard-schneider-9894792

Bertarelli Foundation Gene Therapy Platform

bernard.schneider@epfl.ch